Andrew Goldberg Biography and Net Worth



Andrew serves as a portfolio manager at Marshall Wace, a leading asset management firm, where he helps lead the XO Healthcare Innovation Fund. Before this, and since February 2016, he served as a partner on the innovation team at Vivo Capital, a global healthcare investment firm focused exclusively on the life sciences industry. Prior to this, Andrew was a consultant at McKinsey & Company, where he served pharmaceutical, medical device and biotechnology companies across a range of strategy, M&A, sales, marketing and product development topics. Andrew is a US board-certified physician in both critical care and emergency medicine. He served as an instructor in medicine at the Mayo Clinic College of Medicine in Rochester, MN, from January 2013 to June 2013, where he also completed a fellowship in critical care medicine and served as an attending physician in the Department of Emergency Medicine. Prior to this, Andrew completed emergency medicine residency training at the Los Angeles County + University of Southern California Medical Center (LAC+USC). Andrew has contributed to more than 25 scientific publications in leading peer-reviewed journals, including JAMA, Resuscitation and the Cleveland Clinic Journal of Medicine and his research spans a variety of topics, from traumatic brain injury and cardiac arrest to biomarker analysis and healthcare quality.

Andrew received his MD from The George Washington University School of Medicine in Washington, DC, and a postdoctoral diploma in translational science from the Mayo Clinic Graduate School of Biomedical Sciences. He has held academic and clinical appointments at Oregon Health & Science University, the University of Arizona, the Washington Township Medical Foundation and the Banner Health System.

What is Andrew D. Goldberg's net worth?

The estimated net worth of Andrew D. Goldberg is at least $144,270.00 as of December 15th, 2023. Dr. Goldberg owns 3,000 shares of Tarsus Pharmaceuticals stock worth more than $144,270 as of March 15th. This net worth estimate does not reflect any other investments that Dr. Goldberg may own. Learn More about Andrew D. Goldberg's net worth.

How do I contact Andrew D. Goldberg?

The corporate mailing address for Dr. Goldberg and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at ir@tarsusrx.com. Learn More on Andrew D. Goldberg's contact information.

Has Andrew D. Goldberg been buying or selling shares of Tarsus Pharmaceuticals?

Andrew D. Goldberg has not been actively trading shares of Tarsus Pharmaceuticals within the last three months. Most recently, on Friday, December 15th, Andrew D. Goldberg bought 1,000 shares of Tarsus Pharmaceuticals stock. The stock was acquired at an average cost of $18.96 per share, with a total value of $18,960.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company's stock, valued at $56,880. Learn More on Andrew D. Goldberg's trading history.

Who are Tarsus Pharmaceuticals' active insiders?

Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), Andrew Goldberg (Director), Leonard Greenstein (CFO), Elizabeth Lin (Director), Aziz Mottiwala (Insider), Seshadri Neervannan (COO), Bryan Wahl (General Counsel), and Dianne Whitfield (Chief Human Resources Officer). Learn More on Tarsus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Tarsus Pharmaceuticals?

During the last year, insiders at the sold shares 4 times. They sold a total of 24,496 shares worth more than $749,577.60. The most recent insider tranaction occured on March, 18th when insider Aziz Mottiwala sold 4,766 shares worth more than $145,839.60. Insiders at Tarsus Pharmaceuticals own 8.3% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.

Information on this page was last updated on 3/18/2024.

Andrew D. Goldberg Insider Trading History at Tarsus Pharmaceuticals

See Full Table

Andrew D. Goldberg Buying and Selling Activity at Tarsus Pharmaceuticals

This chart shows Andrew D Goldberg's buying and selling at Tarsus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10k$0$10kTotal Insider BuyingTotal Insider Selling

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $48.09
Low: $45.60
High: $48.23

50 Day Range

MA: $49.11
Low: $41.29
High: $56.94

2 Week Range

Now: $48.09
Low: $20.08
High: $57.28

Volume

487,715 shs

Average Volume

639,551 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05